Keywords: Type 2 diabetes; Diabetic kidney disease; Biomarkers; Proteomics EN Type 2 diabetes Diabetic kidney disease Biomarkers Proteomics 1 3 3 10/18/21 20211013 NES 211013 Letter to the Editor Diabetic kidney disease (DKD) with progression to end-stage renal disease (ESRD) is a much-feared diabetes complication. Further, our results indicate that levels of ANGPT1, TNFSF12 and FGF20 are unaffected by glucose normalization in T2D and therefore not prone to variability in response to glucose fluctuations; therefore, fasting samples are not required. Glucose variability, potentiating hyper- or hypoglycemia, positively associates with both micro- and macrovascular diabetes complications [[2]] and may be an independent risk factor, seen by glucose variability accelerating renal injury in rats [[3]]. [Extracted from the article]